BGLC - Bionexus Gene Lab Corp. Stock Price, Fair Value and News

$0.27+0.01 (+3.85%)

Delayed as of 30 Dec 2024, 11:27 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BGLC Price Action

Last 7 days

13.0%

Last 30 days

8.3%

Last 90 days

-40.9%

Trailing 12 Months

-50%

BGLC RSI Chart

BGLC Valuation

Market Cap

4.7M

Price/Earnings (Trailing)

-4.96

Price/Sales (Trailing)

0.5

EV/EBITDA

-0.66

Price/Free Cashflow

-2.59

BGLC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BGLC Fundamentals

BGLC Revenue

Revenue (TTM)

9.3M

Rev. Growth (Yr)

Rev. Growth (Qtr)

33.21%

BGLC Earnings

Earnings (TTM)

-941.6K

Earnings Growth (Yr)

48.44%

Earnings Growth (Qtr)

-775.71%

BGLC Profitability

Operating Margin

13.47%

EBT Margin

-9.93%

Return on Equity

-10.03%

Return on Assets

-8.56%

Free Cashflow Yield

-38.58%

BGLC Investor Care

Shares Dilution (1Y)

1.70%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.8M	9.2M	9.3M	0
2023	10.3M	10.4M	10.3M	9.8M
2022	12.9M	12.3M	11.3M	10.9M
2021	11.8M	13.8M	14.2M	13.4M
2020	0	0	0	11.4M
2019	0	0	0	0
2018	0	0	0	212.3K

Get all data in R, Python etc through our Historical Stock Data APIs

About Bionexus Gene Lab Corp.

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

CEO	Mr. Sook Keng Yeoh
WEBSITE	bionexusgenelab.com
SECTOR	Basic Materials
INDUSTRY	Specialty Chemicals
EMPLOYEES	27

Bionexus Gene Lab Corp. Frequently Asked Questions

What is the ticker symbol for Bionexus Gene Lab Corp.? What does BGLC stand for in stocks?

BGLC is the stock ticker symbol of Bionexus Gene Lab Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bionexus Gene Lab Corp. (BGLC)?

As of Fri Dec 27 2024, market cap of Bionexus Gene Lab Corp. is 4.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BGLC stock?

You can check BGLC's fair value in chart for subscribers.

Is Bionexus Gene Lab Corp. a good stock to buy?

The fair value guage provides a quick view whether BGLC is over valued or under valued. Whether Bionexus Gene Lab Corp. is cheap or expensive depends on the assumptions which impact Bionexus Gene Lab Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BGLC.

What is Bionexus Gene Lab Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 27 2024, BGLC's PE ratio (Price to Earnings) is -4.96 and Price to Sales (PS) ratio is 0.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BGLC PE ratio will change depending on the future growth rate expectations of investors.